For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $19.38 in the prior trading day, Zymeworks BC Inc (NASDAQ: ZYME) closed at $19.12, down -1.34%. In other words, the price has decreased by -$1.34 from its previous closing price. On the day, 0.87 million shares were traded. ZYME stock price reached its highest trading level at $19.98 during the session, while it also had its lowest trading level at $18.865.
Ratios:
Our goal is to gain a better understanding of ZYME by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.69 and its Current Ratio is at 7.69. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On October 14, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $26.
On October 10, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $30.B. Riley Securities initiated its Buy rating on October 10, 2025, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 15 ’25 when EcoR1 Capital, LLC bought 49,502 shares for $11.43 per share. The transaction valued at 565,847 led to the insider holds 17,877,989 shares of the business.
EcoR1 Capital, LLC bought 5,919 shares of ZYME for $69,738 on May 19 ’25. The Director now owns 17,883,908 shares after completing the transaction at $11.78 per share. On Apr 16 ’25, another insider, EcoR1 Capital, LLC, who serves as the Director of the company, bought 73,953 shares for $11.16 each. As a result, the insider paid 825,589 and bolstered with 17,773,727 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 1448060544 and an Enterprise Value of 1174476672. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.79 while its Price-to-Book (P/B) ratio in mrq is 4.31. Its current Enterprise Value per Revenue stands at 9.559 whereas that against EBITDA is -16.176.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.49, which has changed by 0.43975902 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $19.50, while it has fallen to a 52-week low of $9.03. The 50-Day Moving Average of the stock is 15.47%, while the 200-Day Moving Average is calculated to be 38.94%.
Shares Statistics:
The stock has traded on average 639.70K shares per day over the past 3-months and 1105470 shares per day over the last 10 days, according to various share statistics. A total of 74.85M shares are outstanding, with a floating share count of 73.13M. Insiders hold about 3.44% of the company’s shares, while institutions hold 102.24% stake in the company. Shares short for ZYME as of 1760486400 were 7047624 with a Short Ratio of 11.02, compared to 1757894400 on 7156267. Therefore, it implies a Short% of Shares Outstanding of 7047624 and a Short% of Float of 11.91.
Earnings Estimates
Its stock is currently analyzed by 9.0 different market analysts. The consensus estimate for the next quarter is -$0.24, with high estimates of $0.36 and low estimates of -$0.88.
Analysts are recommending an EPS of between $0.01 and -$1.63 for the fiscal current year, implying an average EPS of -$0.86. EPS for the following year is -$0.96, with 9.0 analysts recommending between $0.31 and -$2.02.
Revenue Estimates
8 analysts predict $29.89M in revenue for. The current quarter. It ranges from a high estimate of $53.6M to a low estimate of $18M. As of. The current estimate, Zymeworks BC Inc’s year-ago sales were $16MFor the next quarter, 8 analysts are estimating revenue of $36.92M. There is a high estimate of $93.6M for the next quarter, whereas the lowest estimate is -$8M.
A total of 10 analysts have provided revenue estimates for ZYME’s current fiscal year. The highest revenue estimate was $200.2M, while the lowest revenue estimate was $86M, resulting in an average revenue estimate of $137.28M. In the same quarter a year ago, actual revenue was $76.3MBased on 10 analysts’ estimates, the company’s revenue will be $152.58M in the next fiscal year. The high estimate is $313.26M and the low estimate is $89.28M.
